肉瘤合并新型冠状病毒肺炎患者的人口统计学、结局及危险因素：一项基于CCC19注册库的回顾性队列研究
Demographics, Outcomes, and Risk Factors for Patients with Sarcoma and COVID-19: A CCC19-Registry Based Retrospective Cohort Study.
作者信息
Wagner Michael J, Hennessy Cassandra, Beeghly Alicia, French Benjamin, Shah Dimpy P, Croessmann Sarah, Vilar-Compte Diana, Ruiz-Garcia Erika, Ingham Matthew, Schwartz Gary K, Painter Corrie A, Chugh Rashmi, Fecher Leslie, Park Cathleen, Zamulko Olga, Trent Jonathan C, Subbiah Vivek, Khaki Ali Raza, Tachiki Lisa, Nakasone Elizabeth S, Loggers Elizabeth T, Labaki Chris, Saliby Renee Maria, McKay Rana R, Ajmera Archana, Griffiths Elizabeth A, Puzanov Igor, Tap William D, Hwang Clara, Tejwani Sheela, Jhawar Sachin R, Hayes-Lattin Brandon, Wulff-Burchfield Elizabeth, Kasi Anup, Reuben Daniel Y, Nagaraj Gayathri, Joshi Monika, Polimera Hyma, Kulkarni Amit A, Esfahani Khashayar, Kwon Daniel H, Paoluzzi Luca, Bilen Mehmet A, Durbin Eric B, Grivas Petros, Warner Jeremy L, Davis Elizabeth J
机构信息
Department of Medicine, University of Washington, and Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
出版信息
Cancers (Basel). 2022 Sep 5;14(17):4334. doi: 10.3390/cancers14174334.
BACKGROUND
Patients with sarcoma often require individualized treatment strategies and are likely to receive aggressive immunosuppressive therapies, which may place them at higher risk for severe COVID-19. We aimed to describe demographics, risk factors, and outcomes for patients with sarcoma and COVID-19.
METHODS
We performed a retrospective cohort study of patients with sarcoma and COVID-19 reported to the COVID-19 and Cancer Consortium (CCC19) registry (NCT04354701) from 17 March 2020 to 30 September 2021. Demographics, sarcoma histologic type, treatments, and COVID-19 outcomes were analyzed.
RESULTS
of 281 patients, 49% ( = 139) were hospitalized, 33% ( = 93) received supplemental oxygen, 11% ( = 31) were admitted to the ICU, and 6% ( = 16) received mechanical ventilation. A total of 23 (8%) died within 30 days of COVID-19 diagnosis and 44 (16%) died overall at the time of analysis. When evaluated by sarcoma subtype, patients with bone sarcoma and COVID-19 had a higher mortality rate than patients from a matched SEER cohort (13.5% vs 4.4%). Older age, poor performance status, recent systemic anti-cancer therapy, and lung metastases all contributed to higher COVID-19 severity.
CONCLUSIONS
Patients with sarcoma have high rates of severe COVID-19 and those with bone sarcoma may have the greatest risk of death.
背景
肉瘤患者通常需要个体化治疗策略，且可能接受积极的免疫抑制治疗，这可能使他们面临患重症 COVID-19 的更高风险。我们旨在描述肉瘤合并 COVID-19 患者的人口统计学特征、风险因素及预后情况。
方法
我们对 2020 年 3 月 17 日至 2021 年 9 月 30 日期间向 COVID-19 与癌症联盟（CCC19）登记处（NCT04354701）报告的肉瘤合并 COVID-19 患者进行了一项回顾性队列研究。分析了人口统计学特征、肉瘤组织学类型、治疗情况及 COVID-19 预后。
结果
在 281 例患者中，49%（n = 139）住院治疗，33%（n = 93）接受吸氧，11%（n = 31）入住重症监护病房（ICU），6%（n = 16）接受机械通气。共有 23 例（8%）在 COVID-19 诊断后 30 天内死亡，44 例（16%）在分析时总体死亡。按肉瘤亚型评估时，骨肉瘤合并 COVID-19 患者的死亡率高于匹配的监测、流行病学与结果（SEER）队列患者（13.5% 对 4.4%）。年龄较大、体能状态较差、近期接受全身抗癌治疗及肺转移均导致 COVID-19 病情更严重。
结论
肉瘤患者患重症 COVID-19 的比例较高，其中骨肉瘤患者的死亡风险可能最大。
Zotero 插件